Anticoagulation and bleeding risk in patients with COVID-19.

ABSTRACT:

Background

There is no current standardized approach to anticoagulation in patients with Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study characterizes the patterns of anticoagulation use in COVID-19 patients and the risk of related bleeding.

Methods

This is a single center retrospective analysis of 355 adult patients with confirmed diagnosis of COVID-19 from March 1 to May 31, 2020. Chi-square was used to analyze the relationship between degree of anticoagulant dose and bleeding events by site. Multivariable logistic regression was used to look at factors associated with inpatient death.

Results

61% of patients were being treated with prophylactic doses of anticoagulation, while 7% and 29% were being treated with sub-therapeutic an

SUBMITTER: Musoke N 

PROVIDER: S-EPMC7444469 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature